Stock Scorecard
Stock Summary for Ovid Therapeutics Inc (OVID) - $1.43 as of 2/6/2026 6:32:55 PM EST
Total Score
12 out of 30
Safety Score
21 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for OVID
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for OVID
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for OVID
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for OVID
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for OVID (21 out of 100)
| Stock Price Rating (Max of 10) | 2 |
| Historical Stock Price Rating (Max of 10) | 2 |
| Stock Price Trend (Max of 10) | 2 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for OVID
Financial Details for OVID
Company Overview |
|
|---|---|
| Ticker | OVID |
| Company Name | Ovid Therapeutics Inc |
| Country | USA |
| Description | Ovid Therapeutics Inc. is a biopharmaceutical firm headquartered in New York, dedicated to developing innovative therapies for neurological disorders, with a particular emphasis on epilepsy. The company leverages its extensive expertise in neurology to address significant unmet medical needs and enhance treatment modalities, fostering improved patient outcomes. Ovid's well-established pipeline showcases a range of promising therapeutic candidates that have the potential to drive notable advancements within the biopharmaceutical landscape. As Ovid continues to prioritize patient quality of life, it remains a key player in delivering transformative therapies aimed at alleviating the burdens of neurological conditions. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 3/10/2026 |
Stock Price History |
|
| Last Day Price | 1.43 |
| Price 4 Years Ago | 1.86 |
| Last Day Price Updated | 2/6/2026 6:32:55 PM EST |
| Last Day Volume | 1,488,729 |
| Average Daily Volume | 1,696,395 |
| 52-Week High | 2.01 |
| 52-Week Low | 0.24 |
| Last Price to 52 Week Low | 495.83% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 23.21 |
| Sector PE | 34.82 |
| 5-Year Average PE | -2.40 |
| Free Cash Flow Ratio | 4.93 |
| Industry Free Cash Flow Ratio | 12.52 |
| Sector Free Cash Flow Ratio | 33.33 |
| Current Ratio Most Recent Quarter | 4.24 |
| Total Cash Per Share | 0.29 |
| Book Value Per Share Most Recent Quarter | 0.63 |
| Price to Book Ratio | 2.49 |
| Industry Price to Book Ratio | 53.70 |
| Sector Price to Book Ratio | 53.77 |
| Price to Sales Ratio Twelve Trailing Months | 16.70 |
| Industry Price to Sales Ratio Twelve Trailing Months | 21.10 |
| Sector Price to Sales Ratio Twelve Trailing Months | 17.66 |
| Analyst Buy Ratings | 11 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 71,212,000 |
| Market Capitalization | 101,833,160 |
| Institutional Ownership | 33.70% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 49.50% |
| Reported EPS 12 Trailing Months | -0.50 |
| Reported EPS Past Year | -0.37 |
| Reported EPS Prior Year | -0.38 |
| Net Income Twelve Trailing Months | -36,330,000 |
| Net Income Past Year | -26,433,000 |
| Net Income Prior Year | -52,339,000 |
| Quarterly Revenue Growth YOY | -23.70% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | -9,487.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 20,611,000 |
| Total Cash Past Year | 26,301,000 |
| Total Cash Prior Year | 27,042,000 |
| Net Cash Position Most Recent Quarter | 20,611,000 |
| Net Cash Position Past Year | 26,301,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 68,226,000 |
| Total Stockholder Equity Prior Year | 87,797,000 |
| Total Stockholder Equity Most Recent Quarter | 44,698,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -37,978,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.53 |
| Free Cash Flow Past Year | -56,027,000 |
| Free Cash Flow Prior Year | -45,918,380 |
Options |
|
| Put/Call Ratio | 10.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.02 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 1.28 |
| 20-Day Bollinger Middle Band | 1.59 |
| 20-Day Bollinger Upper Band | 1.90 |
| Beta | 0.26 |
| RSI | 44.09 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 2/5/2026 1:26:23 AM EST |